Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma
City Of Hope National Medical Center · Beth Israel Deaconess Medical Center · +5 more institutions
Abstract
One hundred ninety-two patients were enrolled between April 1997 and July 2000. Toxicities were as anticipated for these regimens. The response rate was 23.2% (22 of 95 patients) for HD IL-2 versus 9.9% (nine of 91 patients) for IL-2/IFN (P = .018). Ten patients receiving HD IL-2 were progression-free at 3 years versus three patients receiving IL-2 and IFN (P = .082). The median response durations were 24 and 15 [corrected] months (P = .18) [corrected] and median survivals were 17.5 and 13 months (P = .24). For patients with bone or liver metastases (P = .001) or a primary tumor in place (P = .040), survival was superior with HD IL-2.
This randomized phase III trial provides additional evidence that HD IL-2 should remain the preferred therapy for selected patients with metastatic renal cell carcinoma.
Citation impact
- FWCI
- 37.43
- Percentile
- 100%
- References
- 23
Authors
18- DFDavid F. McDermottCorresponding
City Of Hope National Medical Center, Beth Israel Deaconess Medical Center, Loyola University Chicago, University of Illinois Chicago, City of Hope, Dana-Farber Cancer Institute, Indiana University – Purdue University Indianapolis
- MMMeredith M. Regan
City Of Hope National Medical Center, Beth Israel Deaconess Medical Center, Loyola University Chicago, University of Illinois Chicago, City of Hope, Dana-Farber Cancer Institute, Indiana University – Purdue University Indianapolis
- JIJoseph I. Clark
City Of Hope National Medical Center, Beth Israel Deaconess Medical Center, Loyola University Chicago, University of Illinois Chicago, City of Hope, Dana-Farber Cancer Institute, Indiana University – Purdue University Indianapolis
- LELawrence E. Flaherty
City Of Hope National Medical Center, Beth Israel Deaconess Medical Center, Loyola University Chicago, University of Illinois Chicago, City of Hope, Dana-Farber Cancer Institute, Indiana University – Purdue University Indianapolis
- GRGeoffrey R. Weiss
City Of Hope National Medical Center, Beth Israel Deaconess Medical Center, Loyola University Chicago, University of Illinois Chicago, City of Hope, Dana-Farber Cancer Institute, Indiana University – Purdue University Indianapolis
Topics & keywords
- Medicine
- Renal cell carcinoma
- Gastroenterology
- Internal medicine
- Randomized controlled trial
- Carcinoma
- Surgery
- Urology
- Good health and well-being